Text Size
Trial record 4 of 2937 for:    Blood Coagulation Disorders: Clinical Trials
Previous Study | Return to List | Next Study

Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.

This study is currently recruiting participants.
Verified February 2013 by University Children's Hospital, Zurich
Sponsor:
Information provided by (Responsible Party):
University Children's Hospital, Zurich
ClinicalTrials.gov Identifier:
NCT01487837
First received: December 5, 2011
Last updated: February 13, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to compare two different thromboelastometry (ROTEM) trigger levels for administration of human fibrinogen concentrate (Haemocomplettan P) in the treatment of perioperative dilutional coagulopathy during major pediatric surgery. The study hypothesis is that administration of fibrinogen concentrate triggered by a ROTEM FibTEM MCF < 13 mm might reduce the total amount of transfused red cell concentrate during 24 hours after start of surgery as compared to a trigger level of ROTEM FibTEM MCF < 8 mm.


Condition Intervention Phase
Blood Coagulation Disorders
Hemorrhage
 Drug: Human fibrinogen concentrate
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery

Resource links provided by NLM:

Drug Information available for: Fibrinogen
U.S. FDA Resources

Further study details as provided by University Children's Hospital, Zurich:

Primary Outcome Measures:
  • Total amount of transfused red cell concentrate [ Time Frame: 24 hours after start of surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • coagulation measurements [ Time Frame: 24 hours after start of surgery ] [ Designated as safety issue: No ]
    influence on viscoelastic coagulation measurements (ROTEM), plasmatic coagulation testing, FXIII levels, and endogenous thrombin potential

  • length of stay on PICU [ Time Frame: 14 days after surgery or discharge of hospital, whatever occurs earlier ] [ Designated as safety issue: No ]
  • Additional transfusion/blood products requirements [ Time Frame: 24 hours after start of surgery ] [ Designated as safety issue: No ]
  • Occurence of re-bleeding, surgical revision [ Time Frame: 14 days after surgery or discharge of hospital, whatever occurs earlier ] [ Designated as safety issue: No ]
  • Occurence of (severe) adverse events [ Time Frame: 14 days after surgery or discharge of hospital, whatever occurs earlier ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: January 2012
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fibrinogen if FibTEM < 8 mm
Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
 Drug: Human fibrinogen concentrate
Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
Other Name: Haemocomplettan P, CSL Behring
Experimental: Fibrinogen if FibTEM < 13 mm
Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
 Drug: Human fibrinogen concentrate
Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
Other Name: Haemocomplettan P, CSL Behring

  Eligibility

Ages Eligible for Study:   6 Months to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and Females
  • Age 6 months to 17 years
  • Scheduled for elective scoliosis surgery or major craniofacial surgery
  • Written informed consent has been obtained
  • Intraoperative hypofibrinogenemia according to definition of treatment groups

Exclusion Criteria:

  • Preexisting congenital or acquired coagulation disorder
  • Medical history of estimated increased bleeding tendency
  • Ongoing coagulation therapy
  • Clinical signs or diagnosis of acute thromboembolism
  • Intolerance of study drug
  • Participation at another clinical trial
  • Pregnant or lactating women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01487837

Contacts
Contact: Thorsten Haas, MD +41 44 266 ext 8152 thorsten.haas@kispi.uzh.ch
Contact: Markus Schmugge, MD +41 44 266 ext 7182 markus.schmugge@kispi.uzh.ch

Locations
Switzerland
Zurich University Children's Hospital Recruiting
Zurich, Switzerland, 8032
Contact: Thorsten Haas, MD     +41 44 266 ext 8152     thorsten.haas@kispi.uzh.ch    
Principal Investigator: Thorsten Haas, MD            
Sponsors and Collaborators
University Children's Hospital, Zurich
Investigators
Principal Investigator: Thorsten Haas, MD Zurich University Children's Hospital
  More Information

No publications provided

Responsible Party: University Children's Hospital, Zurich
ClinicalTrials.gov Identifier: NCT01487837     History of Changes
Other Study ID Numbers: KEK-ZH-Nr. 2011-0440
Study First Received: December 5, 2011
Last Updated: February 13, 2013
Health Authority: Switzerland: Swissmedic

Keywords provided by University Children's Hospital, Zurich:
Fibrinogen
Blood coagulation disorders
Postoperative bleeding
Transfusions

Additional relevant MeSH terms:
Blood Coagulation Disorders
Hemostatic Disorders
Hemorrhage
Hematologic Diseases
 Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013